
	Herman Rosenman was most recently the senior vice president of finance and chief financial officer of Gen-Probe Inc., where he was instrumental in its September 2002 IPO and its August 2012 sale to Hologic Inc. for $3.7 billion. Prior to joining Gen-Probe, he was president and chief executive officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, and president and chief executive officer of RadNet Management Inc., a large healthcare provider. At RadNet, he developed and implemented strategies that resulted in the company&rsquo;s successful turnaround. Before this, he was the chief financial officer of Rexene Corp., a Fortune 1000 company in the petrochemicals industry, where he led its successful $150 million IPO and $500 million debt financing. Prior to Rexene, Mr. Rosenman was a partner at Coopers &amp; Lybrand (now PricewaterhouseCoopers LLP), where he served numerous Fortune 1000 clients, principally in the pharmaceuticals and telecommunications industries.

	Mr. Rosenman currently serves as chairman of the audit committees of Oxford Immunotec Ltd., Medistem Inc. and VIVUS Inc., where he is also a member of their compensation committees. In addition, he is a member of the advisory board for Scripps Clinics/Green Hospital in San Diego. A C.P.A., Mr. Rosenman received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
